Physician profile
David Addley
NPI 1881767374
$5,135.03
in general payments reported to CMS, 2019-2025
22 companies · $58.30 in 2025
The $58.30 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $802 · 2020: $469 · 2021: $703 · 2022: $1,816 · 2023: $1,277 · 2024: $10.61 · 2025: $58.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $750 · Food and Beverage: $596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $750.00 |
| Food and Beverage | $595.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $2,554.87 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $664.33 | 2019-2023 | |
| Pfizer INC. | $587.02 | 2019-2023 | |
| Impulse Dynamics (USA) INC. | $211.83 | 2022-2023 | Optimizer |
| Medtronic, INC. | $200.14 | 2021 | |
| Philips North America LLC | $102.73 | 2022-2023 | |
| Astrazeneca Pharmaceuticals Lp | $90.31 | 2020-2023 | Farxiga |
| Akcea Therapeutics, INC. | $87.11 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.53 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $76.07 | 2019-2022 | |
| Boston Scientific Corporation | $73.64 | 2019-2023 | Watchman Access System |
| Janssen Pharmaceuticals, INC | $72.27 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $67.49 | 2021-2023 | Verquvo |
| Biotronik INC. | $58.56 | 2021 | |
| Amgen INC. | $54.83 | 2019-2023 | Repatha |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $44.03 | 2019-2020 | |
| Edwards Lifesciences Corporation | $23.85 | 2019 | |
| Amarin Pharma, INC. | $19.16 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18.29 | 2019 | |
| Lantheus Medical Imaging, INC. | $17.91 | 2020 | |
| Abbott Laboratories | $17.00 | 2022 | |
| Esperion Therapeutics, INC. | $13.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Addley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.